Aquestive Therapeutics, Inc. current report, 14 March 2024

Full document

Business Context and Reporting Period

Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: March 14, 2024
Context: The filing discloses positive topline clinical data from a Phase 3 pivotal pharmacokinetic (PK) study of Anaphylm™ (epinephrine) Sublingual Film and findings from a recent FDA Type C meeting. Anaphylm is an orally administered epinephrine prodrug candidate for treating severe allergic reactions.

Key Financial Metrics

This Form 8-K is a current report regarding clinical developments and regulatory interactions. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.

Material Changes and Clinical Findings

The filing details significant progress in the Anaphylm development program compared to prior expectations:

  • Phase 3 Single Dose Study (64 subjects):
    • Cmax: Achieved a geometric mean of 470 pg/mL, bracketed by AUVI-Q (521 pg/mL) and EpiPen (469 pg/mL).
    • Onset (Tmax): Median time to maximum concentration was 12 minutes, faster than EpiPen (20 min), AUVI-Q (30 min), and Adrenalin (50 min).
    • Threshold: Reached 100 pg/mL as rapidly as EpiPen and faster than Adrenalin.
    • Safety: Consistently well tolerated with no Serious Adverse Events (SAEs).
  • Phase 3 Repeat Dose Study (36 subjects):
    • Maintained plasma concentrations equal to or greater than injection products at all but one timepoint out to 2 hours.
    • Median Tmax of 10 minutes after the second dose.
    • Reached/exceeded 100 pg/mL threshold 5 minutes after second dosing.
  • FDA Type C Meeting:
    • FDA indicated the Company "adequately addressed" previous concerns regarding product hold time and emesis characterization.
    • FDA recommended a new study assessing PK performance after oral exposure to a known allergen (replacing the planned angioedema study) to be executed in Q2 2024.
    • FDA noted substantial progress and did not outline new clinical development requirements, though PK sustainability remains a focus.

Guidance, Outlook, and Risks

Outlook and Timeline:

  • Q2 2024: Execution of the Allergen PK Study (replacing angioedema study) and Temperature PK Study.
  • Q3 2024: Self-administration PK Study.
  • H2 2024: Pediatric PK Study and Pre-NDA Meeting.
  • Goal: File the New Drug Application (NDA) with the FDA before the end of 2024.
Risks and Contingencies:
  • Success of the NDA filing depends on the results of ongoing and planned studies.
  • FDA may require additional clinical studies or data justification for epinephrine concentrations above known EpiPen levels.
  • Risks include insufficient capital, delays in clinical trials, regulatory hurdles, and market acceptance.
  • Forward-looking statements are subject to uncertainties including global economic conditions and geopolitical events.

Investor Verification Checklist

  • Verify the specific results of the Q2 2024 Allergen PK Study, as this was a new FDA recommendation.
  • Monitor the timing and outcome of the Pre-NDA meeting scheduled for H2 2024.
  • Confirm the Company's ability to secure sufficient capital to fund the remaining clinical studies and NDA filing before year-end 2024.
  • Review the FDA's final determination on the sufficiency of the clinical development program post-Pre-NDA meeting.
  • Assess the competitive landscape for epinephrine delivery systems given the focus on PK sustainability and safety.